Are Patients and Their Providers Talking About Long-Acting Injectable Antiretroviral Therapy? Penetration into Clinical Encounters at Three U.S. Care Sites

Abstract

Use of long-acting injectable antiretroviral therapy (LAI-ART) depends on patient awareness, provider discussion, and patient willingness to use. We conducted a post-visit survey with patients at three HIV clinics in San Francisco, Chicago, and Atlanta in May 2021 to assess for inequities in these early implementation phases.

Likelihood of trying long-acting injectable antiretroviral therapy (LAI ART) among women with HIV in nine sites across the United States

“…Our study builds upon, and extends, prior research by identifying significant differences in women's likelihood to try LAI ART by age, substance use history, self-reported ART adherence, and geographic region. 15,20 Owing to the dearth of women included in clinical trials, additional research is needed to better understand their varying perspectives, which can inform the tailoring of interventions, messaging, and outreach. For example, WLWH in Miami, FL, merit further consideration to explore whether potential regional cultural barriers and variations in clinical culture may contribute to a lower interest in LAI compared with other sites, even after controlling for sociodemographic factors.…”

“…19 Some studies examined individuals' LAI ART interest in "realworld" settings, although much of this research was conducted before the availability of LAI ART, making responses hypothetical. 15,20,21 Women constituted a minority of clinical trial participants, yet have a variety of experiences and preferences, which uniquely impact ART adherence [11][12][13][14] ; despite this, no studies to date have focused exclusively on women. Qualitative research conducted among WLWH suggests heterogeneity in women's interest in LAI ART, including which populations could most benefit: these included younger people, women with child-rearing and caretaking responsibilities, and women who use substances.…”

Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States

“…Early insights into motivations for and barriers to uptake of efficacious interventions can help guard against challenges that may stymie implementation success and provide new lenses through which to view implementation efforts [ 16 , 17 ]. Surveys of PWH prior to the clinical availability of LAI-ART demonstrated substantive hypothetical willingness to use this treatment alternative, ranging from 55 to 88%, with the highest interest observed among adolescents, young adults, and individuals facing adherence challenges [ 18 – 22 ]. The desire to lessen adherence concerns and the convenience of non-daily dosing emerged as primary motivators for considering LAI-ART, underscoring the weight imposed on PWH by daily oral ART regimens [ 21 , 22 ].…”

Antiviral supramolecular polymeric hydrogels by self-assembly of tenofovir-bearing peptide amphiphiles

“…1 There is substantial patient interest in long-acting treatment strategies, including long-acting injectable (LAI) formulations, for the management of chronic infections resulting from hepatitis B virus (HBV) and human immunodeficiency virus (HIV). [2][3][4][5][6] Such therapeutic formu-lations are necessary to meet the diverse needs of the patient population, thereby improving quality of life and treatment adherence. [6][7][8][9][10][11] Tenofovir (TFV) is a crucial frontline treatment for both chronic HBV and HIV, successfully controlling viral replication and consequently slowing progression to severe disease.…”